Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Journal of Biological Chemistry

Volumn 288, Issue 8, 2013, Pages 5463-5474

  Wu, Fayi ^a   Peacock, Stephanie O ^a,b   Rao, Shuyun ^a   Lemmon, Sandra K ^a   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; BINDING PARTNERS; CO-ACTIVATION; EXCHANGE FACTORS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMAN PROSTATE CANCER; PROSTATE CANCER CELLS; PROSTATE CANCERS; THERAPEUTIC TARGETS; TRANSCRIPTIONAL ACTIVITY;

CELL PROLIFERATION;

DISEASES;

ANDROGEN RECEPTOR; CELL CYCLE PROTEIN 37; PROTEIN VAV3; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; CHAPERONINS; COS CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEK293 CELLS; HUMANS; MALE; MOLECULAR CHAPERONES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-VAV; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84874324273     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.390963     Document Type: Article

References (59)

1. Heemers, H. V., and Tindall, D. J. (2007) Androgen receptor (AR) coregulators. A diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778-808
2. Knudsen, K. E., and Penning, T. M. (2010) Partners in crime. Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 21, 315-324
3. Yuan, X., and Balk, S. P. (2009) Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 27, 36-41
4. Lyons, L. S., and Burnstein, K. L. (2006) Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol. Endocrinol. 20, 1061-1072
5. Dong, Z., Liu, Y., Lu, S., Wang, A., Lee, K., Wang, L. H., Revelo, M., and Lu, S. (2006) Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol. Endocrinol. 20, 2315-2325
6. Banach-Petrosky, W., Jessen, W. J., Ouyang, X., Gao, H., Rao, J., Quinn, J., Aronow, B. J., and Abate-Shen, C. (2007) Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1;Pten mutant mice. Cancer Res. 67, 9089-9096
7. Schmidt, L. J., Regan, K. M., Anderson, S. K., Sun, Z., Ballman, K. V., and Tindall, D. J. (2009) Effects of the 5'-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate 69, 1730-1743
8. Marques, R. B., Dits, N. F., Erkens-Schulze, S., van Weerden, W. M., and Jenster, G. (2010) Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 5, e13500
9. Lin, K. T., Gong, J., Li, C. F., Jang, T. H., Chen, W. L., Chen, H. J., and Wang, L. H. (2012) Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res. 72, 3000-3009
10. Liu, Y., Mo, J. Q., Hu, Q., Boivin, G., Levin, L., Lu, S., Yang, D., Dong, Z., and Lu, S. (2008) Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res. 68, 6396-6406
11. Rao, S., Lyons, L. S., Fahrenholtz, C. D., Wu, F., Farooq, A., Balkan, W., and Burnstein, K. L. (2012) A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene 31, 716-727
12. Salhia, B., Tran, N. L., Chan, A., Wolf, A., Nakada, M., Rutka, F., Ennis, M., McDonough, W. S., Berens, M. E., Symons, M., and Rutka, J. T. (2008) The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am. J. Pathol. 173, 1828-1838
13. Colomba, A., Courilleau, D., Ramel, D., Billadeau, D. D., Espinos, E., Delsol, G., Payrastre, B., and Gaits-Iacovoni, F. (2008) Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-2736
14. Lin, K. Y., Wang, L. H., Hseu, Y. C., Fang, C. L., Yang, H. L., Kumar, K. J., Tai, C., and Uen, Y. H. (2012) Clinical significance of increased guanine nucleotide exchange factor vav3 expression in human gastric cancer. Mol. Cancer Res. 10, 750-759
15. Rosenblatt, A. E., Garcia, M. I., Lyons, L., Xie, Y., Maiorino, C., Désiré, L., Slingerland, J., and Burnstein, K. L. (2011) Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr. Relat. Cancer 18, 207-219
16. Bustelo, X. R. (2000) Regulatory and signaling properties of the Vav family. Mol. Cell Biol. 20, 1461-1477
17. Askew, E. B., Minges, J. T., Hnat, A. T., and Wilson, E. M. (2012) Structural features discriminate androgen receptor N/C terminal and coactivator interactions. Mol. Cell Endocrinol. 348, 403-410
18. Hunter, T., and Poon, R. Y. (1997) Cdc37. A protein kinase chaperone? Trends Cell Biol. 7, 157-161
19. MacLean, M., and Picard, D. (2003) Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones 8, 114-119
20. Pearl, L. H. (2005) Hsp90 and Cdc37. A chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15, 55-61
21. Wang, X., Grammatikakis, N., and Hu, J. (2002) Role of p50/CDC37 in hepadnavirus assembly and replication. J. Biol. Chem. 277, 24361-24367
22. Kimura, Y., Rutherford, S. L., Miyata, Y., Yahara, I., Freeman, B. C., Yue, L., Morimoto, R. I., and Lindquist, S. (1997) Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev. 11, 1775-1785
23. Lee, P., Rao, J., Fliss, A., Yang, E., Garrett, S., and Caplan, A. J. (2002) The Cdc37 protein kinase-binding domain is sufficient for protein kinase activity and cell viability. J. Cell Biol. 159, 1051-1059
24. Abbas-Terki, T., Donzé, O., and Picard, D. (2000) The molecular chaperone Cdc37 is required for Ste11 function and pheromone-induced cell cycle arrest. FEBS Lett. 467, 111-116
25. Rao, J., Lee, P., Benzeno, S., Cardozo, C., Albertus, J., Robins, D. M., and Caplan, A. J. (2001) Functional interaction of human Cdc37 with the androgen receptor but not with the glucocorticoid receptor. J. Biol. Chem. 276, 5814-5820
26. Schutz, A. R., Giddings, T. H., Jr., Steiner, E., and Winey, M. (1997) The yeast CDC37 gene interacts with MPS1 and is required for proper execution of spindle pole body duplication. J. Cell Biol. 136, 969-982
27. Tatebe, H., and Shiozaki, K. (2003) Identification of Cdc37 as a novel regulator of the stress-responsive mitogen-activated protein kinase. Mol. Cell Biol. 23, 5132-5142
28. Stepanova, L., Yang, G., DeMayo, F., Wheeler, T. M., Finegold, M., Thompson, T. C., and Harper, J. W. (2000) Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 19, 2186-2193
29. Markus, S. M., Taneja, S. S., Logan, S. K., Li, W., Ha, S., Hittelman, A. B., Rogatsky, I., and Garabedian, M. J. (2002) Identification and characterization of ART-27, a novel coactivator for the androgen receptorNterminus. Mol. Biol. Cell 13, 670-682
30. Malanchuk, O. M., Pozur, V., Panasyuk, G. G., Nemazanyy, I. O., Filonenko, V. V., Gout, I. T., and Palchevskyy, S. S. (2005) Identification of novel binding partners for tuberous sclerosis complex 2 (TSC2) by yeast two-hybrid approach. Exp. Oncol. 27, 186-190
31. Fields, S., and Song, O. (1989) A novel genetic system to detect proteinprotein interactions. Nature 340, 245-246
32. Gyuris, J., Golemis, E., Chertkov, H., and Brent, R. (1993) Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75, 791-803
33. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1118
34. Zhuang, S. H., and Burnstein, K. L. (1998) Antiproliferative effect of 1-,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistentG1 accumulation. Endocrinology 139, 1197-1207
35. Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., and Burnstein, K. L. (2008) Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol. Endocrinol. 22, 597-608
36. Sramkoski, R. M., Pretlow, T. G., 2nd, Giaconia, J. M., Pretlow, T. P., Schwartz, S., Sy, M. S., Marengo, S. R., Rhim, J. S., Zhang, D., Jacobberger, J. W. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev. Biol. Anim. 35, 403-409
37. Vaughan, C. K., Mollapour, M., Smith, J. R., Truman, A., Hu, B., Good, V. M., Panaretou, B., Neckers, L., Clarke, P. A., Workman, P., Piper, P. W., Prodromou, C., and Pearl, L. H. (2008) Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 31, 886-895
38. Bandhakavi, S., McCann, R. O., Hanna, D. E., Glover, C. V. (2003) A positive feedback loop between protein kinase CKII and Cdc37 promotes the activity of multiple protein kinases. J. Biol. Chem. 278, 2829-2836
39. Miyata, Y., and Nishida, E. (2005) CK2 binds, phosphorylates, and regulates its pivotal substrate Cdc37, an Hsp90-cochaperone. Mol. Cell Biochem. 274, 171-179
40. Shao, J., Prince, T., Hartson, S. D., and Matts, R. L. (2003) Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. 278, 38117-38120
41. Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., and Gronemeyer, H. (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15, 3667-3675
42. Berrevoets, C. A., Doesburg, P., Steketee, K., Trapman, J., and Brinkmann, A. O. (1998) Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol. 12, 1172-1183
43. Shao, J., Irwin, A., Hartson, S. D., and Matts, R. L. (2003) Functional dissection of cdc37. Characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry 42, 12577-12588
44. Movilla, N., and Bustelo, X. R. (1999) Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell Biol. 19, 7870-7885
45. Zeng, L., Sachdev, P., Yan, L., Chan, J. L., Trenkle, T., McClelland, M., Welsh, J., and Wang, L. H. (2000) Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol. Cell Biol. 20, 9212-9224
46. Yabana, N., and Shibuya, M. (2002) Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity. Oncogene 21, 7720-7729
47. Hartl, F. U., and Hayer-Hartl, M. (2002) Molecular chaperones in the cytosol. From nascent chain to folded protein. Science 295, 1852-1858
48. Terasawa, K., Minami, M., and Minami, Y. (2005) Constantly updated knowledge of Hsp90. J. Biochem. 137, 443-447
49. Siligardi, G., Panaretou, B., Meyer, P., Singh, S., Woolfson, D. N., Piper, P. W., Pearl, L. H., and Prodromou, C. (2002) Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem. 277, 20151-20159
50. Roe, S. M., Ali, M. M., Meyer, P., Vaughan, C. K., Panaretou, B., Piper, P. W., Prodromou, C., and Pearl, L. H. (2004) The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116, 87-98
51. Gray, P. J., Jr., Stevenson, M. A., and Calderwood, S. K. (2007) Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67, 11942-11950
52. Lyu, J., Wesselschmidt, R. L., and Lu, W. (2009) Cdc37 regulates Ryk signaling by stabilizing the cleaved Ryk intracellular domain. J. Biol. Chem. 284, 12940-12948
53. Heinlein, C. A., and Chang, C. (2002) Androgen receptor (AR) coregulators. An overview. Endocr. Rev. 23, 175-200
54. Kim, Y. S., Alarcon, S. V., Lee, S., Lee, M. J., Giaccone, G., Neckers, L., and Trepel, J. B. (2009) Update on Hsp90 inhibitors in clinical trial. Curr. Top Med. Chem. 9, 1479-1492
55. Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C., and Liu, G. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940-7946
56. Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bubley, G., Goddard, J., Dunbar, J., and Ross, R. W. (2011) Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78, 626-630
57. Yano, A., Tsutsumi, S., Soga, S., Lee, M. J., Trepel, J., Osada, H., and Neckers, L. (2008) Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl. Acad. Sci. U.S.A. 105, 15541-15546
58. Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., Nelson, C., and Gleave, M. (2007) Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67, 10455-10465
59. Trepel, J., Mollapour, M., Giaccone, G., and Neckers, L. (2010) Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537-549